Gastrointestinal Symptoms : Some individuals might experience nausea, vomiting, diarrhea, or an upset stomach
AOD-9604 offers a gentler approach with more selective fat targeting and fewer systemic effects, making it suitable for individuals who cannot tolerate GLP-1 agonists or prefer a more focused mechanism
Without diet and exercise, any effect of the injection would be minimal
Because AOD9604 is not FDAapproved and cannot be compounded under current guidance, it is offered only under a strict informed consent framework with full transparency about its investigational status, potential risks, and mixed efficacy data
The injections are fairly easy and painless And it works
This is because we cant absorb it as well from food